Safety and efficacy of ibrutinib in combination with rituximab and lenalidomide in previously untreated follicular and marginal zone lymphoma: An open label, phase 2 study.
Max J GordonLei FengPaolo StratiHun Ju LeeFredrick B HagemeisterJason R WestinFelipe SamaniegoMario L Marques-PiubelliFrancisco Vega VazquezEdwin R Parra CuentasLuisa M Solis-SotoWencai MaJing WangLinda ClaretBarbara AverillKarina IbanezLuis E FayadChristopher R FlowersMichael R GreenR Eric DavisSattva S NeelapuNathan H FowlerLoretta J NastoupilPublished in: Cancer (2023)
IRR is highly active as frontline therapy for FL and MZL. Compared to historical results with lenalidomide and rituximab, PFS is similar with higher grade 3-4 toxicity, particularly rash. The study was registered with ClinicalTrials.gov (NCT02532257).